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Background. Hazards of liver surgery have been attenuated by the evolution in methods of hepatic vascular control and
the anesthetic management. In this paper, the anesthetic considerations during hepatic vascular occlusion techniques were
reviewed. Methods.AMedlineliteraturesearchusingtheterms“anesthetic,”“anesthesia,”“liver,”“hepatectomy,”“inﬂow,”“outﬂow
occlusion,” “Pringle,” “hemodynamic,” “air embolism,” “blood loss,” “transfusion,” “ischemia-reperfusion,” “preconditioning,”
was performed. Results. Task-orientated anesthetic management, according to the performed method of hepatic vascular
occlusion, ameliorates the surgical outcome and improves the morbidity and mortality rates, following liver surgery. Conclusions.
Hepatic vascular occlusion techniques share common anesthetic considerations in terms of preoperative assessment, monitoring,
induction, and maintenance of anesthesia. On the other hand, the hemodynamic management, the prevention of vascular air
embolism, blood transfusion, and liver injury are plausible when the anesthetic plan is scheduled according to the method of
hepatic vascular occlusion performed.
1.Introduction
Hepatectomy is one of the therapies available for benign and
malignant liver disease. Although liver resections have been
associated with high mortality and morbidity rates, recent
advances in anesthetic and surgical management have signif-
icantly reduced the operative risk. The techniques of vascular
control during hepatectomy are highly demanding and
should be performed under special anesthetic considera-
tions.
Hepatic vascular control methods can be categorized as
those involving occlusion of liver inﬂow and those involving
occlusion of both liver inﬂow and outﬂow. They can be sum-
marized as following.
(1) Inﬂow vascular occlusion.
(A) Hepatic pedicle occlusion:
(a) Continuous Pringle maneuver (CPM),
(b) intermittent Pringle maneuver (IPM).
(B) Selective inﬂow occlusion.
(2) Inﬂow and outﬂow vascular exclusion
(A) Total hepatic vascular exclusion (THVE),
(B) inﬂow occlusion with extraparenchymal con-
trolofthemajorhepaticveins:withselectivehe-
patic vascular exclusion (SHVE).2 HPB Surgery
When performing these techniques, the conduct of anes-
thesia should take into account hemodynamic management,
risks of vascular air embolism, ischemia reperfusion liver
injury, intraoperative blood loss, and the need for trans-
fusion, factors which usually complicate hepatic vascular
control methods. Special attention should also be paid to the
preoperative assessment and induction of anesthesia, as
patients undergoing liver resection usually have a compro-
mised health status. Careful selection of the anesthetic drugs
can minimize the eﬀects of hepatic blood ﬂow decrease
induced by the surgical technique adopted.
2. Methods
A comprehensive literature search was performed. Our ob-
jective was to identify the anesthetic considerations in tech-
niques of hepatic vascular control methods. Articles were
selected by a Medline literature search, according to the fol-
lowing criteria.
(1) All prospective randomized studies were thoroughly
evaluated and presented, as they are the most im-
portant source of information on the outcomes of
surgical and anesthetic manipulations.
(2) Large retrospective studies were also included. Few
case reports and smaller studies are mentioned, given
the fact that they highlight special anesthetic aspects.
3. Results
3.1. Preoperative Assessment. Healthy patients undergo a
routine preoperative assessment including a full blood count
and a standard biochemical and coagulation test.
Preexisting hepatic impairment is a risk factor, even
for nonhepatic surgery, with higher blood transfusion re-
quirements, a longer hospital stay, a higher number of com-
plications,andincreasedmortalityratesof16.3%incirrhotic
patients as compared to 3.5% in controls [1]. Estimating
the health status of patients presenting for hepatectomy is
quite challenging: coagulopathy, volume and electrolyte dis-
turbances, viral infections (Hep C), hepatorenal [2–4]a n d
hepatopulmonary[3]syndrome,portopulmonary hyperten-
sion, and low cardiovascular reserve capacity can occur in
patients with chronic liver disease.
The identiﬁcation of patients at risk to develop post-
operative hepatic or renal failure is important and, ideally,
involves many related disciplines such as surgery, anesthesia,
and intensive care. Although vascular occlusion techniques
have minimized hepatic bleeding, the risk for postoperative
liver and/or renal failure remains high for patients of
advanced age and those with steatosis and cirrhosis, on
preoperative chemotherapy and with small remnant liver
volumes [5]. Slankamenac et al. [6] have developed and
validated a prediction score for postoperative acute liver
failure following liver resection based on the preoperative
parameters of cardiovascular disease, chronic liver failure,
diabetes, and ALT levels, which seems to be an easily
applicable and attractive tool in clinical practice.
Vascular control techniques during hepatectomy require
optimization of the cardiac and pulmonary function [7].
Hepatic ischemia and reperfusion on subsequent liver dys-
function is associated with unexpected responses to surgical
stress [7–9] and poor prognosis [10]. Patients with end-
stage liver disease have a characteristic hemodynamic proﬁle:
increased cardiac output with blunted response to painful
stimuli, splanchnic vasodilatation and central hypovolemia.
As a result, silent moderate-to-severe coronary artery disease
cannot be easily recognized. Currently, there are no speciﬁc
guidelines for the identiﬁcation of coronary artery disease in
patients with advanced liver disease [11, 12]. Preoperative
invasive assessment of preexisting cardiovascular dysfunc-
tion is indicated only for high risk patients, provided that
anycoagulopathyiscorrected[11].Inthenoninvasiveassess-
ment of coronary artery disease in patients with cirrhosis,
dobutaminestressechocardiographyhasfailedasascreening
tool [12]. Furthermore, beta blockade discontinuation in
order to permit adequate cardiac function assessment may
be hazardous in patients with advanced liver disease [12].
Beta blockers reduce portal hypertension, decrease cardiac
workload, and their use seems to be beneﬁcial to both the
liver and the heart in the setting of hepatectomy.
In general, the preoperative assessment needs to be
adapted to the individual patient to minimize the periopera-
tive liver insults of hepatic vascular control.
3.2. Induction and Maintenance of Anesthesia. Liver resec-
tions are usually performed under general anesthesia with
tracheal intubation and controlled ventilation. Patients with
ascites undergo rapid sequence induction [13]. Cis-atracuri-
um is the nondepolarizing muscle relaxant of choice in pa-
tients with liver disease as it is hydrolyzed by Hoﬀman elimi-
nation. Moreover, it is haemodynamically stable due to its
scarce release of histamine [14]. Atracurium can provide
stableneuromuscularblockade,asitsrequirementsremained
unchanged during exclusion of the liver from the circulation
[15].
An intravenous hypnotic is used for induction and a
halogenated volatile agent in air-oxygen mixture is used
for maintenance [16]. Hepatic vascular control techniques
depresscardiovascularfunctioninadditiontothedepression
caused by general anesthesia. Careful selection of the volatile
agent is required. Most commonly used volatile anesthetics
for maintenance are isoﬂurane and sevoﬂurane. Isoﬂurane
has mild cardiodepressive eﬀects but maintains hepatic oxy-
gen supply, due to vasodilatation in the hepatic artery and
portal vein [17]. Both isoﬂurane and sevoﬂurane upregulate
heme-oxygenase-1, release iron and carbon monoxide, and
thus decrease portal vascular resistance in rats [18]. In
humans, sevoﬂurane decreases portal vein blood ﬂow but
increases hepatic artery blood ﬂow [19]. In addition, Beck-
Schimmer et al., in a randomized controlled trial on patients
undergoing liver surgery [20], showed that ischemic precon-
ditioning with sevoﬂurane before inﬂow occlusion limited
postoperative liver injury, even in patients with steatosis.
Although various inhalational anesthetics are used in liver
surgery, no optimal anesthetic technique has been estab-
lished for the maintenance of anesthesia. Desﬂurane appearsHPB Surgery 3
Table 1: Hemodynamic changes on clinical series of hepatectomies induced by hepatic vascular occlusion techniques.
Technique Haemodynamic changes
Heart rate Mean arterial blood pressure Cardiac index
Inﬂow and outﬂow occlusion
THVE∗
Redai et al.a [16] ↑ 25% ↓ 17,64% ↓ 50%
Smyrniotis et al.a [123] ↑ 21% ↓ 23% ↓ 50%
Figueras et al.a [124] ↑ 18,75% ↓ 20,48% ↓ 60%
Smyrniotis et al. [54] ↑ 29% ↑ 22% ↓ 50%
SHVE∗∗
Figueras et al.a [124] ↑ 2,46% ↑ 3,79% N/A
Smyrniotis et al. [54] ↑ 5% ↑ 5,55% ↓ 10%
Inﬂow occlusion
Pringle
Redai et al.a [16] ↑ 6.25% ↑ 15% ↓ 10%
Smyrniotis et al.a [123] ↑ 12% ↑ 16% ↓ 10%
Figueras et al.a [124] ↑ 8.83% ↑ 13.85% N/A
aValues expressing % change of heart rate, mean arterial blood pressure, and cardiac index during clamping and uclamping of hepatic vessels.
∗THVE: total hepatic vascular exclusion.
∗∗SHVE: selective hepatic vascular exclusion.
↑: increase.
↓:r e d u c t i o n .
to have no greater liver toxicity than currently used volatile
anesthetic agents [21]. Additionally, desﬂurane undergoes
only minor biodegradation (it is metabolized at a ratio of
0.02%) and in fact it may cause less hepatocellular damage
duetoitsreducedmetabolism[21].Koetal.[22],comparing
theeﬀectsofdesﬂuraneandsevoﬂuraneonhepaticandrenal
functions after right hepatectomy in living donors reported
better postoperative hepatic and renal function tests with
desﬂurane as compared to sevoﬂurane at equivalent doses of
1 MAC without, however, being able to validate the clinical
importance of their study. Arslan et al. [23] comparing the
eﬀects of anesthesia with desﬂurane and enﬂurane on liver
function, showed that during anesthesia with desﬂurane,
liver function was well preserved; glutathione-S-transferase
and aspartate aminotransferase levels were signiﬁcantly
lower in the desﬂurane group. On the other hand, Laviolle et
al. [24] suggested that propofol has an early protective eﬀect
against hepatic injury compared with desﬂurane after partial
hepatectomy under inﬂow occlusion.
It is now generally accepted that anesthesia reduces
hepatic blood ﬂow. However, few studies on the eﬀects of
generalanesthesia during hepatectomies under vascularcon-
trol techniques are available in patients with signiﬁcant com-
orbidities.
3.3. Hemodynamic Management
3.3.1.InﬂowVascularOcclusion. CPM,IPM,andselectivein-
ﬂow occlusion share common hemodynamic management.
Portal triad clamping increases systematic vascular resistance
by up to 40% and reduces cardiac output by 10%. Mean
arterial pressure increases about 15% (Table 1). Following
unclamping, hemodynamic parameters gradually return to
baseline values [25–28]. However, the systemic circulation in
patients with cirrhosis is hyperdynamic and dysfunctional,
with increased heart rate and cardiac output, decreased
systemic vascular resistance, and low or normal arterial
blood pressure. Thus, maintaining adequate organ perfusion
may be diﬃcult to achieve and preoperative optimization of
the patient is required.
The anesthetic management is dictated by the surgical
approachandthepatient’shealthstatus.Forhealthypatients,
routine monitoring is used. Monitoring can even be limited
to just peripheral vein catheters [29]. Invasive monitoring
provided by a central venous line or pulmonary catheteriza-
tion is reserved for patients with poor cardiovascular status
or when prolonged vascular occlusions are performed.
A low CVP (between 2 and 5mmHg), while aiming
at euvolemia, reduces blood loss during liver surgery and
improves survival [30, 31]. A low CVP can be achieved
by limitation of intravenous ﬂuids administration pre- and
intraoperatively.Maintenanceﬂuidsandcrystalloidstostabi-
lize blood pressure >90mmHg and ensure diuresis of at least
0.5mL/kg/h can be used safely with minor hemodynamic
disturbance [32]. If ﬂuid restriction is ineﬀective to keep a
low CVP, vasoactive agents are used. Nitroglycerin reduces
CVP to the desired level during the resection phase or
when excessive oozing is observed from the resected surface
[13, 16]. Intravenous morphine has also been used for its
hypotensive eﬀect.
CPM with a CVP of 5mmHg or less is associated with
minor blood loss and a shorter hospital stay [33]. IPM may
result in ﬂuctuations of systemic blood pressure. If, however,
it is applied under a low CVP during transection, blood
loss and hemodynamic changes are minimal [34–37]. In an
experimental animal study, Sivelestat, a neutrophil elastase
inhibitor, reduced hepatic injury and stabilized hemo-
dynamics after ischemia-reperfusion following IPM [38].4 HPB Surgery
The advantages of a low CVP must be weighed against
inadequate perfusion of the vital organs and loss of volemic
reserve in case of bleeding and/or air embolism. A 15◦ Tren-
delenburg position protects against air embolism. Melendez
et al. [34] support that in low CVP anesthesia during liver
resection, the incidence of perioperative renal failure does
not increase signiﬁcantly.
3.3.2. Inﬂow and Outﬂow Vascular Occlusion
(1) Total Hepatic Vascular Exclusion (THVE). In THVE, rap-
id hemodynamic changes (Table 1) are frequent due to sur-
gical events such as caval clamping, sudden blood loss,
and hepatic reperfusion. Cross-clamping of the inferior
vena cava and portal vein result in a 40–60% reduction
of venous return and cardiac output, with a compensatory
80% increase in systemic vascular resistance and a 50%
increase in heart rate. Although systemic vascular resistance
and heart rate increase, the cardiac index is reduced by half,
secondary to a preload reduction. Unclamping is followed by
an increase in cardiac index and a signiﬁcant reduction in
systemic vascular resistance [39].
The anesthetist should take prompt steps to manage the
preload reduction and the sudden decrease in cardiac output
evoked by the inferior vena cava and portal vein clamping.
Intraoperative monitoring includes ECG, pulse oximetry,
ETCO2 tension, invasive blood pressure monitoring through
an arterial line, and CVP monitoring through a large bore
central venous line. Patients with pulmonary hypertension
require pulmonary artery catheterization. In addition, the
presence of a pulmonary artery catheter allows the tailored
administration of vasopressors in case of massive hemor-
rhage due to vena cava injury. The Vigileo, an uncalibrated
arterial pulse contour cardiac output monitoring system,
has been proved to be unreliable in cirrhotic patients with
hyperdynamic circulation undergoing major liver surgery
[40].
Before THVE, colloids can be administered to prevent
the abrupt decrease in cardiac output. Colloids, beyond cor-
recting volume deﬁcits [33], improve splanchnic circulation,
displaceﬂuidintothebloodcompartment,andreducebowel
edema. Blood pressure and circulatory support is achieved
by aiming at a CVP of at least 14mmHg [16]. Vasopressin
or norepinephrine are administered if volume loading is
inadequate to maintain blood pressure following clamping
of the vena cava [7].
There is no standard approach to the use of vasoactive
agents in THVE. Most studies have mainly been performed
in septic patients or in animal models. Vasoactive agents
should be used carefully, as they improve cardiac output at
the expense of microcirculatory blood ﬂow. During vascular
isolation of the liver in eight pigs, norepinephrine infusion
(0.7µg/kg/min) decreased hepatic vascular capacitance by
activation [41]. In a recent study in septic patients, Krejci
et al. [42] showed that norepinephrine increased systemic
blood ﬂow but reduced microcirculatory blood ﬂow on
liver’s surface.
Vasopressin on the other hand, is known to rapidly
restore blood pressure during septic shock. However, in an
experimental study [43], vasopressin proved to be inferior
to norepinephrine in terms of improving hepatosplanchnic
blood ﬂow. The response to both norepinephrine and
vasopressin is blunted in patients with cirrhosis [44, 45].
Preventing renal impairment is another important con-
sideration for the anesthesiologist. Renal autoregulation
ceases below a renal perfusion pressure of 70 to 75mmHg,
below which, ﬂow becomes pressure dependent. Periopera-
tive ﬂuid shifts, intravascular hypovolemia, and sympathetic
activation during THVE result in a reduction of renal
blood ﬂow. Mannitol, furosemide, and “low dose dopamine”
have been used with the aim of preventing intraoperative
renal injury without evidence of substantial beneﬁt [46].
Fenoldopam had beneﬁcial eﬀects [47]o np o s t o p e r a t i v ec r e -
atinine levels and creatinine clearance of critically ill patients
[48].Recently,terlipressinalongwithvolumeexpansionhave
been shown to improve renal function, without, however,
improving survival [49].
Hemodynamic intolerance to THVE or ischemia under
THVE exceeding 30 or 60 minutes, require venovenous
bypass [50, 51]. THVE should be limited to selected cases,
as hemodynamic intolerance has been observed in 10–20%
of patients, as well as increased morbidity and hospital stays
(Table 2).
(2) Selective Hepatic Vascular Exclusion (SHVE). SHVE is
a ﬂexible technique that can be applied in a continuous
or intermittent manner. Should accidental tears of major
hepatic veins occur, rapid conversion to THVE must be
undertaken. The literature suggests that many institutions
favor SHVE as one of the standard methods of vascular con-
trol because it provides a bloodless surgical ﬁeld and it is
tolerated by most patients. No special anesthetic considera-
tions regarding the hemodynamic management of SHVE are
referred, as this method diminishes blood pressure and heart
rate ﬂuctuations during liver resection (Table 1).
In a cohort study [52] among 246 patients, hemody-
namic tolerance to SHVE was excellent with only a slight
increaseinsystemicandpulmonaryresistanceduringclamp-
ing. No deaths were reported and the mean hospital stay was
9.6 days.
SHVE is the method of choice in cases when CVP cannot
be lowered (i.e., right heart failure, poor cardiovascular sta-
tus) [53–56]. In a retrospective study on 102 patients, SHVE
was shown to be unaﬀected by CVP levels and the authors
concludedthatitshouldbeusedwheneverCVPremainshigh
despite adequate anesthetic management [57]. Although the
performance of SHVE requires signiﬁcant surgical expertise,
it is tolerated by most patients and has a hemodynamic
proﬁle similar to that of CPM [53, 54]. Furthermore, it
controls backﬂow bleeding of the hepatic veins. In a large
clinical study [58], SHVE proved to be more eﬀective
than CPM in controlling intraoperative bleeding, preventing
blood loss, and reducing postoperative complications and
mortalityrates(Table 2).CombinedSHVEandperioperative
ﬂuid restriction has also been suggested as a liver and renal
protective procedure in partial hepatectomy. Moug et al. [59]
demonstrated that active preoperative dehydration of theHPB Surgery 5
Table 2: Clinical series of hepatectomies performed under vascular occlusion techniques.
Technique-study No. of
patients
Type of hepatectomya Clamp time (min) Morbidity/mortality (%) Transfusions (%) CVP
(mmHg)
I.Pb
Torzilli et al. [36] 329 Major 71% 69 26/0 3.9 N/A
Nuzzo et al. [125] 120 Major 38% 39 N/A 60 <5
Omar Giovanardi et al. [126] 72 Major 81% N/A 24/7 57 N/A
THVEc
Smyrniotis et al. [54] 18 Major 32 33/0 30 N/A
Figueras et al. [124] 39 N/A 41 N/A 4 6.4
SHVEd
Smyrniotis et al. [54] 20 Major 38 25/0 15 <5
Zhou et al. [58] 125 N/A 21.7 39.2/0 32 4.4
Fu et al. [127] 246 Major N/A 24.8/0 24 2–5
Figueras et al. [124] 41 N/A 47 N/A 6 7.2
Pringle-IPMe
Wang et al. [98] 114 N/A N/A N/A 13.1 5–10
Zhou et al. [58] 110 N/A 22.5 51.8/1.8 80.9 4.6
Ishizaki et al. [128] 380 Major 39.4% 62 23.9/0 34 N/A
aMajor hepatectomy is deﬁned as resection of more than two segments according to Couinaud’s classiﬁcation.
bI.P: ischemic preconditioning.
cTHVE: total hepatic vascular exclusion.
dSHVE: selective hepatic vascular exclusion.
eIPM: intermittent pringle maneuver.
patient, low CVP anesthesia and SHVE resulted in minimal
blood loss, low morbidity, and zero mortality in patients
undergoing partial liver resection.
In conclusion, SHVE which is not associated with car-
diorespiratoryandhemodynamicalterationsiswelltolerated
by the majority of patients and requires shorter hospitaliza-
tion times [54].
3.4. Vascular Air Embolism. Although the relative risk of air
embolism in hepatic surgery is low (<5%) [60], several cases
have been reported during liver vascular control techniques.
Factors predisposing to vascular air embolism during liver
resections include: (a) surgical technique, (b) size and place
of the tumor, (c) blood loss, and (d) low CVP anesthesia.
Clinical signs of vascular air embolism during anesthesia
with respiratory monitoring are: a decrease in end-tidal car-
bon dioxide and decreases in both arterial oxygen saturation
(SaO2) and tension (PO2), along with hypercapnia. From
the cardiovascular system monitoring, tachyarrhythmias,
electromechanical dissociation, pulseless electrical activity as
well as ST-T changes can be noted. Major hemodynamic
manifestationssuchassuddenh ypotensionmayoccurbefore
hypoxemia becomes present.
When performing techniques of inﬂow vascular occlu-
sion (CPM, IPM, selective inﬂow occlusion), air embolism
may be observed during parenchymal transection under low
CVP anesthesia or during reperfusion, due to mobilization
of air bubbles trapped in opened veins. Resection of large
tumors situated in the right lobe [61], close to the inferior
vena cava or the cavohepatic junction, put the patient at risk
of venous air embolism. Those tumors should therefore be
resected under THVE or SHVE if possible. Recent clinical
trials assessing the eﬃcacy of SHVE and Pringle maneuver
in preventing vascular air embolism showed that embolism
occurred in three out of 2100 patients or in one out of 29
patients of the Pringle group, following massive blood loss
during tumor resection. Air embolism did not occur in any
case of the SHVE group [62–64].
Massive bleeding (>5000mL) and subsequent air
embolism can even result in intraoperative death in patients
undergoing major liver resections [65]. The morbidity and
mortality of air embolism depend on the volume and rate
of air accumulation [66]. From case reports of accidental
intravascular delivery of air, the adult lethal volume has been
described as between 200 and 300mL or 3–5mL/kg [67, 68].
Low CVP further enhances the negative pressure gradient at
the surgical ﬁeld compared to the right atrium and increases
the possibility of air embolism.
Currently, the most sensitive monitoring devices for
vascular air embolism are transesophageal echocardiography
andprecordialDopplerultrasonography,detectingaslittleas
0.02mL/kg and 0.05mL/kg of air, respectively [69–71].
The consequences of air embolism can be minimized by
placing the patient in a 15 degree Trendelenburg position
[72–74]. However, recent literature has questioned the
eﬃcacy of Trendelenburg position on improving hemody-
namics [75]. Furthermore, Moulton et al. [75] in a small
study among ten patients, showed that patient positioning
alone during liver surgery does not aﬀect the risk of venous
air embolism. Thus, the beneﬁcial eﬀects of low CVP in6 HPB Surgery
liver resections must be carefully weighed against adequate
hydration and volume status optimization.
Vascular air embolism is a potentially hazardous com-
plication. Additionally, cirrhotic patients undergoing hepa-
tectomy have pulmonary abnormalities including intrapul-
monary shunting, pulmonary vascular dilatation, and arteri-
ovenous communications. In these patients, air can pass into
the systemic circulation (paradoxical air embolism), even if
cardiacabnormalities(patentforamenovale)arenotpresent,
evoking fatal consequences [76].
Recent literature suggests that SHVE prevents vascular
air embolism and provides operative tolerance. However,
recognizing the risk for vascular air embolism and planning
the appropriate level of monitoring and treatment is the key
to patient safety.
3.5. Blood Loss and Transfusion. Liver resections may result
in signiﬁcant blood loss and subsequent transfusion of RBC
(redbloodcells)inabout25%–30%ofpatients[77].Thetwo
main sources of bleeding during a liver resection are (a) the
inﬂow system (hepatic artery and portal vein) and (b) the
outﬂow system (backﬂow bleeding from the hepatic veins).
Bleeding may also occur during liver mobilization, hepatic
transection, and dissection of biliary structures.
Blood loss has been linked to morbidity and mortality
since 1989 [8], whereas RBC transfusions are associated with
multiple disadvantages, risks, and side eﬀects. Furthermore,
operative blood loss independently predicts recurrence and
survival after resection of hepatocellular carcinomas [78].
Operative mortality in patients refusing blood transfusions
was 7.1% for patients with hemoglobin levels >10g/dL and
61.5% for patients with hemoglobin levels <6g/dL[79, 80].
The reﬁnement of inﬂow and outﬂow occlusive tech-
niques as well as the appropriate anesthetic management
has reduced intraoperative bleeding and the need for blood
transfusions. The surgical approach to hepatic resection is
of major importance in preventing blood loss. Study of the
literature reveals the following results regarding bleeding
withdiﬀerent vascular occlusion techniques: Pringle maneu-
ver has been shown to be eﬀective in reducing blood loss
during parenchyma transection [81]. Portal triad clamping
is associated with less bleeding compared with no clamping
[82]. In procedures of liver ischemia time < one hour, CPM
is equal to IPM. Belghiti et al. [9], in a prospective study
of IPM versus CPM, found no diﬀerence in total blood loss
or the volume of blood transfused between the two groups,
despite higher blood loss during parenchyma transection.
Man et al., in two prospective studies of IPM versus no use
of vascular control at all, showed lower total blood loss and
fewer transfusions in the IPM group [83–85]. Hemihepatic
vascular clamping was shown superior to IPM and to no
application of vascular control, with reduced both blood
loss and transfusion requirements [86]. SHVE provides
a bloodless surgical ﬁeld similar to THVE, but is better
tolerated by patients. Many authors favor SHVE as one of
the standard methods of vascular control, as it substantially
prevents massive blood loss and diminishes transfusion
needs.
From an anesthetic standpoint, a low CVP level plays
an important role in reducing intraoperative blood loss and
transfusion rates [30, 57, 87]. Maintaining a CVP < 5mmHg
by volume restriction and intravenous infusion of nitroglyc-
erine and a systolic blood pressure above 90mmHg by intra-
venous infusion of dopamine (4–6µg/kg) has dramatically
reduced bleeding and transfusion requirements [88]. The
anesthetist should also provide normothermic conditions to
the patient undergoing liver resection, because hypothermia
reduces blood coagulation, especially platelet function, and
increases intraoperative blood loss.
Alternative methods of diminishing blood loss have
been investigated. Of the pharmacological methods, desmo-
pressin, although used in treating hemophilia, was not
eﬀective in reducing blood loss and transfusion needs in
patients undergoing liver resection. In a randomized clinical
trial, the use of recombinant factor VIIa in major liver
resections failed to reduce the number of units transfused
[89]. A signiﬁcant reduction in blood transfusion needs in
liver resections has been shown with the use of aprotinin.
Aprotinin was found to reduce intraoperative blood loss by
25% and transfusion requirements by 50% [81]. Redai et al.
[16] used half dose aprotinin (106 KIU followed by 2.5 ×
105 KIU/hour infusion) during hepatic transplantation in
patientswhohaveasigniﬁcantcoagulopathyorportalhyper-
tension and in those who had previous abdominal surgery.
However,Lentschneretal.[90]cautionedagainsttheroutine
use of aprotinin due to the incidence of life threatening
allergic reactions, thrombotic potential, and renal failure.
Currently, there is no scientiﬁc support for the routine use
of aprotinin in patients undergoing partial hepatectomy,
whereas its eﬃcacy in liver transplantation is well established
[91]. Tranexamic acid has also been shown to reduce blood
requirements in liver resection surgery but safety concerns
have been raised and require further investigation [92, 93].
In the future, two artiﬁcial oxygen carriers (hemoglobin
solutions and perﬂuorocarbons) may become essential in
reducing the need for allogeneic RBC transfusions [94–96].
A r t i ﬁ c i a lo x y g e nc a r r i e r si m p r o v eO 2 delivery and tissue
oxygenation as well as the function of organs with marginal
O2 supply. More studies examining their eﬃcacy in ischemic
liver during hepatectomy need to be performed.
Undoubtedly, the improvement of vascular control tech-
niques during hepatectomy has permitted an aggressive
approach for liver resections with low mortality rates (4%)
[52]. In addition, anesthesia orientated towards an almost
transfusion free setting has also improved mortality and
morbidity following liver surgery. To this direction, Pulitan` o
et al. [97] proposed a score predicting blood requirements
in liver surgery. A transfusion risk score, including vari-
ables of: (a) preoperative hemoglobin concentrations below
12.5g/dL, (b) largest tumor more than 4cm, (c) need for
exposure of the vena cava, (d) need for an associate proce-
dure, and (e) cirrhosis, accurately predicted the likelihood of
blood transfusions in liver resections.
Recently, Cescon et al. [52], in a retrospective review
assessing the outcome of 1500 consecutive patients who
underwenthepaticresection,estimatedoverallmortalityand
morbidity at 3% and 22.5%, respectively. Their multivariateHPB Surgery 7
analysis revealed that blood transfusions, primary liver
tumors, and additional procedures were associated with an
increased risk of postoperative complications, whereas blood
transfusions, cirrhosis, biliary malignancies, and extended
hepatectomy were associated with an increased risk of post-
operative mortality. Wang et al. [98], evaluating the long-
term outcomes of liver resection for hepatocellular carci-
noma, estimated that 86.9% of the patients did not require
perioperative blood transfusion and that Pringle maneuver
and RBC transfusions are independent prognostic factors
inﬂuencing survival.
Blood transfusions are well known to carry the risk
of transmitted infections, acute or delayed reactions and
“wrong blood” incidents. In liver resections, blood transfu-
sions are associated with suppression of the immune system.
There is strong evidence that blood transfusions have
an impact on tumor recurrence for patients with early
stages of hepatocellular carcinoma. However, no such eﬀect
could be demonstrated for patients undergoing partial
liver resection for late stages of hepatocellular carcinoma,
colorectal metastasis, or cholangiocarcinoma [99]. Trans-
fusion evoked immunosuppression is also responsible for
TRALI (transfusion-related acute lung injury). Dyspnea,
hypotension, fever, and bilateral noncardiogenic pulmonary
edema, present within 6h of transfusion and complicate
the postoperative outcome of patients following major liver
surgery [100]. Patients with chronic liver disease have the
greatest risk of developing TRALI, in comparison to other
populations [101, 102]. Although all blood products can
lead to this life-threatening situation, plasma-containing
products were responsible for the majority of cases in
patientsundergoingliver transplantation[101].Recentstud-
ies suggest that TRALI fatalities followed plasma transfusion
components were linked to multiparous female donors with
leukocyteantibodies[103,104].Therefore,theestablishment
of new strategies in blood donation excluding multiparous
women as donors, as potential carriers of TRALI-inducing
antibodies, is expected to eliminate this entity.
In conclusion, given the inﬂuence of blood loss and
transfusions on the surgical outcome, techniques of liver
vascular control and anesthetic management should be
adjusted to the individual patient. The tumor location, the
underlying liver disease and the patient’s cardiovascular
status should therefore be taken into account, in order to
minimize blood loss and transfusion requirements.
3.6. Ischemia-Reperfusion Injury and Preconditioning. Ische-
mia/reperfusion (I/R) injury is a serious complication of
liver surgery, especially after extended hepatectomies [105].
It causes a local and systemic inﬂammation response and its
clinical manifestations may vary from transient arrhythmias
to multiorgan dysfunction and death [106]. Reperfusion
injury is mediated via reactive oxygen species which damage
cellular membranes, stimulate leukocyte activation and
endothelial adhesion, and activate the complement. All
these pathophysiological changes lead to microcirculatory
failure.HepaticI/Rinjuryaﬀectspatientrecoveryaftermajor
surgery and bears a risk of poor postoperative outcome
[107]. In liver surgery, ischemic preconditioning (IP) and
intermittent clamping are the only established methods to
provide protection against tissue damage due to ischemia
during inﬂow occlusion [98, 108].
IP is deﬁned as a process in which a short period of
ischemia, separated by intermittent reperfusion, renders an
organ more tolerant to subsequent episodes of ischemia
[107, 109]. It was initially described for a canine heart by
Murry et al. in 1986 [110]. As far as the liver is concerned,
the beneﬁcial eﬀect of IP was ﬁrst demonstrated in a rodent
model by Lloris-Carsi et al. [111]. Clavien et al. provided
the ﬁrst clinical evidence of beneﬁt in patients undergo-
ing hemihepatectomy [112]. It leads to improvement of
hepatic microcirculation, reduction in tissue apoptosis, and
improvement of survival. Experimental data suggest that
generationofadenosine,activationofadenosineA2 receptors
with subsequent generation of NO and release of NO cause
vasodilation and prevent the increase in endothelins, thus
protecting the liver from reperfusion injury [107]. IP stim-
ulates adenosine receptors on Kupﬀer cells in nonischemic
lobes to produce oxygen radicals, leading to the promotion
of liver regeneration after partial hepatectomy [113]. In
a clinical study of 61 patients undergoing liver surgery
performed by Heizmann et al., the absence of precondi-
tioning was found to be an independent risk factor for
postoperative complications [114]. The beneﬁt of ischemia
is restricted by old liver [109]. It has been stated that IP
might also be less beneﬁcial during extended liver resections,
due to hyperperfusion-induced derangement in hepatic
microcirculation. Similarly, the eﬀect of preconditioning was
lost in patients undergoing tissue loss above 50% [115].
In small liver remnants of about 30%, it may in fact have
detrimentaleﬀects.Thisisbecausethesmallremainingtissue
suﬀers from shear stress-associated microvascular injury.
Ischemic preconditioning seems to attenuate the apoptotic
response of hepatic cells in major hepatectomies performed
u n d e rS H V E[ 115]. On the other hand, Azoulay et al. found
that IP failed to protect human liver against IR injury after
m a j o rh e p a t e c t o m yu n d e rc o n t i n u o u sv a s c u l a ro c c l u s i o n
withpreservationofcavalﬂow[116].Otherstrategiesshould
be used to induce protection in this setting. Combined
IP and salvialonic acid-B have been shown to possess
synergistically protective eﬀects in rats, mediated through
reduction of postischemic oxidative stress, higher ATP levels
and reduction in hepatocellular apoptosis [105].
The severity of IR injury is related to the duration of
vascular occlusion. The preconditioning eﬀect fades away
when the ischemic time is prolonged [108]. In this case,
intermittent vascular occlusion, although more complex
surgically,seemstobethemethodofchoice.VanWagensveld
et al. demonstrated that prolonged intermittent vascular
inﬂowocclusioninpigliversurgerycausedlessmicrocircula-
tion impairment and hepatocellular necrosis compared with
continuous occlusion and recommend it when a prolonged
period of vascular inﬂow occlusion is expected [117]. It
has been found that when ischemia persists for more than
40 minutes, intermittent vascular occlusion oﬀers better
protection of liver cells, demonstrated by lower AST values,
lower apoptotic activity and reduced capsase-3 activation
[108].8 HPB Surgery
In several animal models, pharmacological precondi-
tioning with a volatile anesthetic has been proven to pro-
vide protection against ischemic injury. Beck-Schimmer
et al. evaluated the eﬀects of sevoﬂurane preconditioning
before liver ischemia and concluded that this particular
volatile anesthetic limited the postoperative increase of
serum transaminase levels by 261U/L for the ALT and by
239U/L for the AST. The sevoﬂurane group had less
major complications (such as sepsis, bilioma, bleeding, and
infection) than the control (propofol) group. The protective
eﬀects were more pronounced in patients with liver steatosis
[20]. However, according to Wang et al., propofol also seems
to have the ability to protect human hepatic L02 cells from
H2O2-induced apoptosis [118]. Intraportal administration
of L-arginine, a precursor of NO, has been recently studied
in pigs and appears to reduce cell damage during the early
phase of reperfusion, by downregulating capsase-3 activty
and by preserving mitochondrial structure. Clinically, it
resultedinareductionofASTandanincreaseinbileproduc-
tion [119]. In another animal study, simvastatin (5mg/kg)
protected the rat liver from I/R injury by regulating the
inﬂammatory response and by improving microvascular
ﬂow [120]. Prostaglandins have also been found to have
protective eﬀects on I/R-injured livers by inhibiting the
generation of reactive oxygen species, preventing leucocyte
migration, improving hepatic insulin and lipid metabolism
and regulating the production of inﬂammatory cytokines.
They are also essential after hepatectomy because they
promote hepatocyte proliferation [121].
Finally, Ramalho et al. reported that angiotensin II
type I receptor (AT1R) antagonist increased regeneration in
nonsteatotic livers, while in the presence of steatosis both
AT1R and AT2R antagonists increased liver regeneration
[122].
4. Conclusions
Hepatic vascular occlusion techniques require anesthetic
expertise. Intolerance to THVE is not unusual and this
method should be reserved for patients in need for extensive
reconstruction of the inferior vena cava. SHVE has the most
favorable intraoperative and postoperative hemodynamic
proﬁle. Inﬂow occlusion techniques, although simple and
eﬀective, require speciﬁc anesthetic manipulations to reduce
liver injury and prevent backﬂow bleeding.
Every method of hepatic vascular control applied under
a carefully selected anesthetic plan can improve the outcome
of patients undergoing hepatectomy. The surgeon and
anesthesiologist must work together eﬀectively. Anesthetic
vigilance along with thorough knowledge of the surgical
manipulations promotes team-based health care in the
operative room.
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